Overview

Location [1]
20q13.12
Protein [2]
Nuclear receptor coactivator 3
Synonyms [1]
KAT13B, SRC3, RAC3, ACTR, TRAM-1, CTG26, SRC-3, bHLHe42, pCIP, AIB-1, TNRC14, TNRC16, CAGH16, AIB1

NCOA3 is altered in 2.56% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, lung adenocarcinoma, cutaneous melanoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].

NCOA3 GENIE Cases - Top Diseases

The most common alterations in NCOA3 are NCOA3 Amplification (1.03%), NCOA3 Loss (0.02%), NCOA3 Q1273_Q1276del (0.02%), NCOA3 L642* (0.01%), and NCOA3 Q1276dup (0.02%) [3].

NCOA3 GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.